{"transactions":[{"id":912487,"issuer":{"id":8261,"kind":"organization","name":"DNA X, Inc."},"owners":[{"id":67080,"kind":"person","name":"Crolius Clayton","position":1,"cik":"0001937013","reported_name":"Crolius Clayton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-11T01:55:33.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (i) 1,719 shares of common stock and (ii) 35,000 unvested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9."}],"balance_after":36719,"source":{"system":"sec-edgar","filing":"0001493152-26-006055","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226006055/ownership.xml","form_type":"4"}},{"id":1165832,"issuer":{"id":8261,"kind":"organization","name":"DNA X, Inc."},"owners":[{"id":67080,"kind":"person","name":"Crolius Clayton","position":1,"cik":"0001937013","reported_name":"Crolius Clayton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-25T12:35:37.000Z","date":"2025-04-23","kind":"sale","planned":false,"acquired":false,"shares":11634,"price":1.45,"value":16869.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.42 to $1.45, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":30958,"source":{"system":"sec-edgar","filing":"0001641172-25-006117","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178697/000164117225006117/ownership.xml","form_type":"4"}},{"id":1276952,"issuer":{"id":8261,"kind":"organization","name":"DNA X, Inc."},"owners":[{"id":67080,"kind":"person","name":"Crolius Clayton","position":1,"cik":"0001937013","reported_name":"Crolius Clayton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-11T02:30:13.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":33922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in two equal installments on the 90th and 180th day following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (i) 8,670 shares of common stock and (ii) 33,922 unvested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of securities reported herein reflects the effects of a 1-for-10 reverse stock split effected by the Issuer on July 17, 2024, which was exempt from reporting pursuant to Rule 16a-9."}],"balance_after":42592,"source":{"system":"sec-edgar","filing":"0001493152-25-005765","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315225005765/ownership.xml","form_type":"4"}},{"id":1544719,"issuer":{"id":8261,"kind":"organization","name":"DNA X, Inc."},"owners":[{"id":67080,"kind":"person","name":"Crolius Clayton","position":1,"cik":"0001937013","reported_name":"Crolius Clayton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right-to-Buy)","published_at":"2024-04-10T00:58:44.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over the next three (3) years in equal yearly installments on each anniversary of the grant date."}],"balance_after":170000,"derivative":{"exercise_price":0.6154,"exercise_date":"2025-04-08","expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001493152-24-014120","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315224014120/ownership.xml","form_type":"4"}},{"id":1729694,"issuer":{"id":8261,"kind":"organization","name":"DNA X, Inc."},"owners":[{"id":67080,"kind":"person","name":"Crolius Clayton","position":1,"cik":"0001937013","reported_name":"Crolius Clayton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right-to-Buy)","published_at":"2023-11-27T23:35:08.000Z","date":"2023-11-24","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in their entirety on the first anniversary of the grant date."}],"balance_after":200000,"derivative":{"exercise_price":0.7,"exercise_date":"2024-11-24","expiration_date":"2033-11-24","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-23-042816","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315223042816/ownership.xml","form_type":"4"}},{"id":1779195,"issuer":{"id":8261,"kind":"organization","name":"DNA X, Inc."},"owners":[{"id":67080,"kind":"person","name":"Crolius Clayton","position":1,"cik":"0001937013","reported_name":"Crolius Clayton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-19T00:45:06.000Z","date":"2023-09-15","kind":"purchase","planned":false,"acquired":true,"shares":86700,"price":0.683,"value":59216.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.635 to $0.71, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":86700,"source":{"system":"sec-edgar","filing":"0001493152-23-032976","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315223032976/ownership.xml","form_type":"4"}},{"id":2040540,"issuer":{"id":8261,"kind":"organization","name":"DNA X, Inc."},"owners":[{"id":67080,"kind":"person","name":"Crolius Clayton","position":1,"cik":"0001937013","reported_name":"Crolius Clayton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right-to-Buy)","published_at":"2023-01-31T23:00:18.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in their entirety on the first anniversary of the grant date."}],"balance_after":100000,"derivative":{"exercise_price":0.494,"exercise_date":"2024-01-27","expiration_date":"2033-01-27","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-23-003189","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315223003189/ownership.xml","form_type":"4"}}]}